SYNOPSIS An improved and optimized method for serum glutathione reductase is described. The reference range for normal subjects is 47-79 IU/1. The method is more sensitive than conventional enzyme tests in the detection of malignant disease. It was not raised more frequently in patients with clinical evidence of metastases than in those clinically free of such metastases, and it did not seem to correlate with prognosis among those patients who failed to survive six months from the time the analysis was first conducted.
Glutathione reductase (GR; NAD(P)H: glutathione oxido reductase EC 1.6.4.2) is an important flavo enzyme involved, with glucose-6-phosphate dehydrogenase, in the maintenance of a reduced intracellular environment. The glucose-6-phosphate dehydrogenase provides NADPH which allows the reduction of oxidized glutathione (GSSG) using the following reaction: GR GSSG + NADPH + H+ * = 2GSH + NADP+ The equilibrium constant strongly favours the formation of reduced glutathione.
Clinical interest in GR has taken several forms. Screening for hereditary erythrocyte GR deficiency has been advocated (Beutler, 1966 ) although this does not necessarily lead to oxidant-induced haemolytic anaemias (Jaffe, 1968) . The prosthetic group of GR is the riboflavin metabolite FAD. The extent of activation of red cell GR by exogenous FAD has been used as a test for riboflavin deficiency (Glatzle et al, 1968; Beutler, 1969; Sauberlich et al, 1972; Heller et al, 1974) . Red cell GR is increased in cystic fibrosis patients (Shapiro et al, 1973) .
Early work showed that the serum enzyme was elevated in many liver diseases (particularly infective hepatitis), pernicious anaemia, and often to a very high level in malignant disease, especially where 'Correspondence to: Dr. D. M. Goldberg, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada Received for publication 15 July 1975. liver metastases were present (Manso and Wr6blew-ski, 1958; Kerppola et al, 1959; West et al, 1961; Horn et al, 1962) .
As approximately 33 % of the patients with cancer in these studies had elevated serum GR levels, and the instrumentation available to the clinical chemist has improved in the decade since these papers were published, the present study was initiated to determine whether, using an automated kinetic determination of GR, the assay was of value in cancer assessment. Initial studies showed that phosphate was superior to triethanolamine and PIPES (piperazine-N, N'-bis (2-ethane-sulphonic acid)), and that varying the molarity between 0-1 and 0 3 mol/l was without effect.
Material and
The inclusion of EDTA in the reaction mixture at a final concentration of 0-5 mmol/l enhanced enzyme activity and raised the pH optimum (fig 1) . This shift in pH optimum occurring when EDTA is included in the reaction mixture allows GR from all sources to be analysed at pH 7-2, and this minimizes blank reactions due to spontaneous hydrolysis of NADPH. EFFECT OF ENZYME ACTIVATORS Dithioerythritol was included in the reaction mixture to a final concentration of 2 mmol/l and had no significant effect on the activity of the serum enzyme. FAD has been shown to activate red cell GR (Glatzle et al, 1968; Beutler, 1969) . Inclusion of FAD in the reaction mixture up to a final concentration of 10 ,umol/l (concentrations above this were slightly inhibitory) had no effect on 37 of 38 randomly selected sera. The single exception was activated by 20% and 65 % at 2 and 10 Hmol/l respectively. The patient concerned had a prostatic carcinoma, and riboflavin deficiency could not be ruled out. (Ticktin aind Trujillo, 1970) and the Regan isoenzyme of ALP (Fishman et al, 1968) . These suffer the disadvantages of poor specificity and a low incidence respectively.
Early work on serum GR showed that one-third of patients with neoplastic disease had elevated activity. The present study was initiated to determine the clinical value of this assay using improved methodology, since current methods proved to be suboptimal, unsuitable for application to reaction rate analysers, or optimized for the erythrocyte enzyme. The use of a reaction rate analyser for the estimation of erythrocyte GR has been described (Brewster et al, 1974) . The method is optimized for very small sample volumes, since high concentrations of haemolysates give unacceptably high initial absorbances, and is not directly applicable to serum. A colourimetric method based upon the quantitative liberation of chlorpromazine from a preformed coloured palladium-chlorpromazine complex by the reduced glutathione produced in the reaction has been described (Lee et al, 1975) . This method is independent of the initial absorbance and has been applied to the estimation of both serum and erythrocyte GR activities.
The inclusion of EDTAin the reaction mixture has long been part of erythrocyte GR assays, and its inclusion in the serum assay is justified by the increase in activity and the shift in pH optimum to a more alkaline region with improved stability of NADPH. Earlier methods employed conditions differing from those we found to be optimal, and a comparison of these with our own is presented in table V.
The observation that the serum enzyme is not activated by FAD, unlike the erythrocyte enzyme (Glatzle et al, 1968; Beutler, 1969) , may reflect a higher extracellular FAD concentration. The GR activity of rat liver homogenates has been shown to be unaffected by exogenous FAD (Menendez et al, 1974 The level of serum GR activity was of no value in assessing the eventual outcome, and in fact GR was a worse prognostic index than any of the other enzymes assayed. AsT was the most promising in this regard since all the patients who had an elevated AsT died within six months of the sample being taken. However, the high incidence of raised serum GR among cancer patients demonstrated in this study suggests that it may be of value in population screening. Since it is raised in liver disease and blood dyscrasias (Manso and Wroblewski, 1958; Kerppola et al, 1959; West et al, 1961; Horn et al, 1962) , serum GR cannot be regarded as a cancer specific test, but it deserves to replace LDH in multiphasic biochemical profilinig. A true assessment of its diagnostic value will emerge only when it is applied to a general hospital population rather than to the restricted case material of a cancer-treatment centre.
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